From the age of 50, men and women can have their stool examined annually using immunological stool tests (iFOBT), and every two years from the age of 55. Colonoscopy is a regular option for men aged 50 and
Durner J. High Throughput Newborn Screening for Sickle Cell Disease - Application of Two-Tiered Testing with a qPCR-Based Primary screen. Clin Padiatr. 2023 Nov;235(6):366-372. doi: 10.1055/a-2153-7789 [...] T, Niedergassel T, Steinhagen K, Meyer-Schlinkmann KM. Dried blood spot eluates are suitable for testing of SARS-CoV-2 IgG antibodies targeting Spike protein 1 and Nucleocapsid protein. Biochem Biophys
inflammation are carried out and the extent to which they are sensitized to certain allergens is tested. In addition to biomaterials (e.g. blood, microbial samples, respiratory secretions), data on symptoms [...] understand the mechanisms at the cellular level. Conversely, identified tolerance signatures will be tested in human biomaterials of the CHAMP cohorts. Another important focus of the working group is on factors
apposite selection of prevention programs which are available throughout Germany and that have been tested for effectiveness and recommendable prevention approaches for children/young people, families, k [...] Walter U (2024). Evidence Register Green List Prevention - Analysis of the listed effectiveness-tested programs. Public Health 2024; 86: 474-482. DOI 10.1055/a-2308-7256 Tetzlaff F, Bremer K , Brender
MHH, research focus on patient orientation and health education Collaboration in projects User testing of health information from the Institute for Quality and Efficiency in Health Care (IQWiG) Promotion [...] H, Hartmann M, Meyer A , Schwarz C, Temucin G, Dierks M-L (2023). Participatory development and testing process of a course concept to promote digital health literacy - "KundiG - Klug und digital durch
came to Hanover for the first operation of this kind worldwide. In the meantime, reBEAT has been tested five times on humans. "There have been no complications, the system has worked excellently and all
how to save the nerve cells," Dr. Höllerhage notes. In the long term, the neurologists then want to test therapy options in clinical trials to treat patients in the Parkinson's preliminary phase neuropr
for other neurodegenerative diseases, the biochemist suspects. Next, the research team would like to test the results in the animal model and use the MS expertise available in Lower Saxony for this. "For
nutrient solution, these heart muscle slices live and continue to beat for many days to weeks. "We first test the mode of action of our circRNA candidates in the living heart slices," says the scientist. In a
cross-site Molecular Tumor Board explicitly does not compete with the basic care of standard molecular tests, which are already being carried out by institutes of pathologists in private practice. This is in